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Acute myocardial infarction (AMI) is a critical clinical 
presentation of coronary artery disease (CAD). As pointed 
out previously by us (1), major clinical research efforts 
have been dedicated to the identification of patients 
at higher risk and to the diagnosis of CAD and AMI. 
Although a great pool of information concerning systemic 
inflammation markers have been so far collected in different 
cardiovascular conditions, the evolution of AMI is not well 
depicted (1). 
CD40 ligand (CD40L) is a signalling molecule (2), 
implicated in thrombosis and inflammatory response to 
vascular injury (3). CD40L binds to CD40 a member of 
tumour necrosis factor family of cell surface interaction 
molecules. Both proteins are expressed on many immune 
cells, such as lymphocytes, monocytes, dendritic cells, 
neutrophils, and mast cells, and on non-immune cells, 
such as platelets and vascular cells (2). CD40L, its 
soluble form sCD40L, and membrane-bound CD40 
determine the inflammatory or immune response through 
secondary messengers, such as cytokines, chemokines and 
transcription factors (2,4), orchestrating the activation and 
recruitment of different leukocyte subsets to the vessel wall 
and inflammation sites (5). 
Previous  s tudies  have demonstrated that  both 
soluble and bound forms of CD40L exert several roles 
in atherothrombosis other than simply supporting cell 
adhesion. Henn et al. (6) proposed that in vivo, once 
platelets were strongly activated in the vascular system, 
CD40L would be rapidly expressed on aggregating cells 
and available to interact with CD40 on the neighbouring 
endothelial cells and on monocytes trapped in the thrombus. 
Furthermore, CD40L could also have a direct participation 
in the thrombotic process either in thrombus stabilization (7) 
or in its formation at the infarct-related artery (8). Several 
studies showed high affinity of soluble CD40L (sCD40L) 
and CD40L for CD40 when TNF-α receptors and integrins 
are expressed (7). sCD40L is also a ligand of glycoprotein 
(GP) IIb/IIIa, and its release from activated platelets can 
be blocked by GP IIb/IIIa antagonists (9,10), suggesting a 
control of sCD40L release by interrupting platelet CD40L/
GP IIb/IIIa axis. sCD40L can induce the formation of 
platelet aggregates, and therefore a role in the coordination 
of different cell types interactions could be proposed to 
CD40L (11).
In the context of CAD several in vitro studies evidenced 
the re levance of  CD40L/sCD40L in endothel ia l 
dysfunction (4,6,10), activation of different types of vascular 
cells (12), leukocyte trafficking and homing (5), among 
other distinctive processes of the atherosclerotic pathology. 
Although a great pool of information concerning CD40L 
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(membrane-bound and soluble forms) have been so far 
collected in different cardiovascular conditions, the onset 
of AMI and its evolution was not well depicted until our 
articles had been published (13,14).
In the Editorial “Measuring soluble CD40 ligand: it 
is a fancy prognostic biomarker in STEMI-patients?” A. 
Dominguez-Rodriguez does not question the validity of our 
results or our methods.
The editorial comment gives indications on what a 
biomarker should be, and recommends that scientific 
research should be limited, suggesting that the existence of 
previous indicators can not justify the search for new and 
better ones.
The author also declares that indicators to evaluate 
myocardial infarction already exist, such as cardiac troponin 
and brain natriuretic peptide. We agree that these two 
indicators are indeed clinically valuable. However, a large 
body of literature has shown that they have a limited 
prediction capacity, whether in terms of risk, infarction 
severity or myocardial recovery. 
Extensive research efforts have been put forward to 
discover new biomarkers with prognostic potential to 
assess myocardial infarction patients, including sCD40L. 
However, before our recent study (13,14) results were not 
conclusive.
Without being “ultra-enthusiastic”, as claimed in 
Dominguez-Rodriguez comment, we believe that our work 
provides a novel approach to this problem, paving the way 
to a previously unforeseen line of research, which seems to 
be very promising.
Indeed, the results of our previous research (13,14) 
have shown that sCD40L has the characteristics of a true 
bioindicator, in the sense that: 
(I) the  magni tude  o f  sCD40L concentra t ions 
correlates with different clinical conditions, clearly 
differentiating patient evolution after myocardial 
infarction; 
(II) sCD40L enables us to predict the disease evolution, 
which is  not  accomplished by the previous 
bioindicators.
We therefore think that we have given a valuable and 
honest contribution to this field, and we do not understand 
the statements or the purpose of these Comments. 
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